Jeffrey H Lipton

Jeffrey H Lipton

UNVERIFIED PROFILE

Are you Jeffrey H Lipton?   Register this Author

Register author
Jeffrey H Lipton

Jeffrey H Lipton

Publications by authors named "Jeffrey H Lipton"

Are you Jeffrey H Lipton?   Register this Author

100Publications

2766Reads

34Profile Views

Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Curr Hematol Malig Rep 2020 Feb 20. Epub 2020 Feb 20.

Division of Cardiology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-020-00560-xDOI Listing
February 2020

Dr Hans August Messner 1941-2018.

Bone Marrow Transplant 2019 Dec 26;54(12):1930-1931. Epub 2019 Feb 26.

Department of Hematology, Ottawa, ON, Canada.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0495-3
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0495-3DOI Listing
December 2019

CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases.

Mult Scler 2019 Dec 17:1352458519892914. Epub 2019 Dec 17.

Division of Oncology, Department of Medicine, University of Toronto and Princess Margaret Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458519892914DOI Listing
December 2019

Avoiding the Thorns of the Gifted Red Rose: Case Report of Late Diagnosis of Polycythemia Rubra Vera in a Sibling Bone Marrow Transplantation Donor for a Patient with Chronic Myeloid Leukemia.

Acta Haematol 2019 Dec 18:1-2. Epub 2019 Dec 18.

Allogeneic Blood and Marrow Transplant Service, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504740DOI Listing
December 2019

My jamais vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults.

Bone Marrow Transplant 2019 Oct 14. Epub 2019 Oct 14.

Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0711-1DOI Listing
October 2019

Progressive multifocal leukoencephalopathy due to John Cunningham (JC) virus following allogeneic haematopoietic cell transplantation.

Antivir Ther 2017 ;22(8):721-725

Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP3162DOI Listing
July 2019

Yet do much less...so much less!

Authors:
Jeffrey H Lipton

Blood 2019 07;134(1):6-7

Princess Margaret Cancer Centre.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019001014DOI Listing
July 2019

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.

Biol Blood Marrow Transplant 2019 06 14;25(6):1158-1163. Epub 2019 Jan 14.

Messner Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.014DOI Listing
June 2019

Patients' perspectives on the definition of cure in chronic myeloid leukemia.

Leuk Res 2019 May 28;80:40-42. Epub 2019 Mar 28.

Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee 53226, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.007DOI Listing
May 2019

Sequential liver and haematopoietic stem cell transplantation in a case of fulminant hepatitis associated liver failure and aplastic anaemia.

Eur J Haematol 2019 Apr 15;102(4):375-377. Epub 2019 Feb 15.

Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13213DOI Listing
April 2019

Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.

Eur J Haematol 2019 Apr 13;102(4):368-374. Epub 2019 Feb 13.

Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13216DOI Listing
April 2019

Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.

Am J Hematol 2019 03 25;94(3):346-357. Epub 2018 Nov 25.

Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25342
Publisher Site
http://dx.doi.org/10.1002/ajh.25342DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587857PMC
March 2019

Resolution of celiac disease, IgA deficiency and platelet refractoriness after allogeneic bone marrow transplantation for acute leukemia.

Haematologica 2019 03 17;104(3):e121-e123. Epub 2019 Jan 17.

University Health Network (UHN), Laboratory Medicine Program (LMP), Department of Laboratory Hematology (Blood Transfusion Laboratory [BTL])

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.203943DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395320PMC
March 2019

Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.

Ann Hematol 2018 Oct 11;97(10):1975-1985. Epub 2018 Jun 11.

Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3391-9DOI Listing
October 2018

Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era.

Leuk Res 2018 10 5;73:67-75. Epub 2018 Sep 5.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.08.021DOI Listing
October 2018

Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients.

Biol Blood Marrow Transplant 2018 09 18;24(9):1901-1905. Epub 2018 Apr 18.

Division of Hematology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183019
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.04.009DOI Listing
September 2018

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia.

Blood Res 2018 Jun 25;53(2):172-174. Epub 2018 Jun 25.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5045/br.2018.53.2.172DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021569PMC
June 2018

Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience.

Eur J Haematol 2018 Mar 11;100(3):308-314. Epub 2018 Jan 11.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13015DOI Listing
March 2018

Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment.

Bone Marrow Transplant 2018 03 15;53(3):334-338. Epub 2017 Dec 15.

Allogeneic Blood And Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, 610 University Ave. Toronto, Ontario, Canada, M5G2M9.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-017-0025-0
Publisher Site
http://dx.doi.org/10.1038/s41409-017-0025-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861088PMC
March 2018

Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation.

Bone Marrow Transplant 2018 03 21;53(3):361-365. Epub 2017 Dec 21.

Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-017-0053-9DOI Listing
March 2018

Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia.

Expert Opin Emerg Drugs 2018 03 3;23(1):51-62. Epub 2018 Mar 3.

a Princess Margaret Cancer Centre , University Health Network , Toronto , ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1445717DOI Listing
March 2018

Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2018 02 3;24(2):366-372. Epub 2017 Oct 3.

Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.09.015DOI Listing
February 2018

Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.

Eur J Haematol 2018 Feb 13;100(2):198-205. Epub 2017 Dec 13.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13000DOI Listing
February 2018

Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1.

Eur J Haematol 2017 Sep 23;99(3):234-239. Epub 2017 Jun 23.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12909DOI Listing
September 2017

Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data.

Eur J Haematol 2017 Aug 30;99(2):160-168. Epub 2017 May 30.

Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12899DOI Listing
August 2017

Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.

Leuk Res 2017 08 16;59:142-148. Epub 2017 Jun 16.

Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.06.009DOI Listing
August 2017

Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.

Biol Blood Marrow Transplant 2017 Jun 27;23(6):945-951. Epub 2017 Feb 27.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.02.015DOI Listing
June 2017

Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.

Ann Hematol 2017 May 18;96(5):805-815. Epub 2017 Feb 18.

Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, 610 University Ave, Toronto, ON, M5G2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-2939-4DOI Listing
May 2017

Current approach to the treatment of chronic myeloid leukaemia.

Leuk Res 2017 04 11;55:65-78. Epub 2017 Jan 11.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126173000
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2017.01.005DOI Listing
April 2017

Everything old is new again: the case for imatinib as frontline therapy in 2017.

Clin Adv Hematol Oncol 2017 Apr;15(4):302-305

Leukemia Site Group, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
April 2017

Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy.

Blood 2017 01 12;129(1):38-47. Epub 2016 Oct 12.

Department of Medical Oncology, Princess Margaret Cancer Center, University Health Network, Faculty of Medicine and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-04-708560DOI Listing
January 2017

Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.

Biol Blood Marrow Transplant 2016 12 3;22(12):2270-2275. Epub 2016 Sep 3.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.08.030DOI Listing
December 2016

Ponatinib in the therapy of chronic myeloid leukemia.

Expert Rev Hematol 2016 Oct;9(10):923-32

a Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre , University of Toronto , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2016.1232163DOI Listing
October 2016

A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.

Expert Opin Drug Saf 2016 Sep 15;15(9):1279-86. Epub 2016 Jul 15.

c Department of Oncology , Sir Mortimer B Davis Jewish General Hospital , Montréal , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2016.1207760DOI Listing
September 2016

Allogeneic Hematopoietic Stem Cell Transplantions in Blastic Plasmacytoid Dendritic Cell Neoplasm in first complete remission: an effective therapy for a rare disease.

Leuk Lymphoma 2016 08 24;57(8):1942-4. Epub 2015 Dec 24.

a Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1115032DOI Listing
August 2016

Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.

Drugs Aging 2016 May;33(5):335-45

Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Rm 5-106, 610, University Avenue, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-016-0351-8DOI Listing
May 2016

Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis.

PLoS One 2015 2;10(4):e0123171. Epub 2015 Apr 2.

Transplant Infectious Diseases, Multi-Organ Transplant Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123171PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383538PMC
April 2016

Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia.

J Transl Med 2016 Mar 24;14:82. Epub 2016 Mar 24.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-016-0837-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806489PMC
March 2016

Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series.

Acta Haematol 2015 9;134(3):161-7. Epub 2015 May 9.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ont., Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000375150DOI Listing
December 2015

Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.

JAMA Oncol 2015 Sep;1(6):729-30

Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaoncol.2015.1024DOI Listing
September 2015

Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report.

J Med Case Rep 2015 Sep 16;9:214. Epub 2015 Sep 16.

Department of Hematology/Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-015-0674-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574179PMC
September 2015

A case report and literature review of chronic graft-versus-host disease manifesting as polymyositis.

Int J Hematol 2015 Jul 3;102(1):144-6. Epub 2015 Mar 3.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Avenue, Toronto, M5G2M9, Canada,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs12185-015-17
Web Search
http://link.springer.com/10.1007/s12185-015-1768-2
Publisher Site
http://dx.doi.org/10.1007/s12185-015-1768-2DOI Listing
July 2015

Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.

Clin Lymphoma Myeloma Leuk 2015 May 5;15(5):e73-81. Epub 2014 Oct 5.

Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2014.09.014DOI Listing
May 2015

Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.

Am J Hematol 2015 May 8;90(5):392-9. Epub 2015 Apr 8.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23955DOI Listing
May 2015

Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning.

Biol Blood Marrow Transplant 2014 Nov 10;20(11):1722-8. Epub 2014 Jul 10.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.06.033DOI Listing
November 2014

Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Biol Blood Marrow Transplant 2014 Nov 17;20(11):1751-7. Epub 2014 Jul 17.

Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.07.001DOI Listing
November 2014

Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts.

Eur J Haematol 2014 Oct 29;93(4):273-80. Epub 2014 Apr 29.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.12338
Publisher Site
http://dx.doi.org/10.1111/ejh.12338DOI Listing
October 2014

Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.

Clin Transplant 2013 Nov-Dec;27(6):930-7. Epub 2013 Nov 5.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ctr.12268DOI Listing
August 2014

BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.

Am J Hematol 2014 Jun 10;89(6):626-32. Epub 2014 Apr 10.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23707DOI Listing
June 2014

Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemia.

Clin Case Rep 2014 Jun 18;2(3):77-8. Epub 2014 Mar 18.

Princess Margaret Cancer Centre Toronto, Ontario, Canada ; University of Toronto 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.49DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184597PMC
June 2014

Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.

Biol Blood Marrow Transplant 2014 Apr 15;20(4):474-9. Epub 2013 Dec 15.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.12.560DOI Listing
April 2014

Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.

Biol Blood Marrow Transplant 2014 Apr 18;20(4):556-63. Epub 2014 Jan 18.

Allogeneic Blood and Marrow Transplantation Program, Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.01.010DOI Listing
April 2014

Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes.

Transfusion 2014 Mar 5;54(3):681-90. Epub 2013 Jul 5.

Blood and Marrow Transplant Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada; Research & Development, Canadian Blood Services, Toronto, Ontario, Canada; Transfusion Medicine Laboratory, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.12329DOI Listing
March 2014

A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Clin Lymphoma Myeloma Leuk 2013 Dec 1;13(6):646-56. Epub 2013 Oct 1.

The University of Texas, MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.05.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784255PMC
December 2013

BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.

Br J Haematol 2013 Mar 24;160(5):630-9. Epub 2012 Dec 24.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12187DOI Listing
March 2013

Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation.

Biol Blood Marrow Transplant 2012 Dec 23;18(12):1905-10. Epub 2012 Jul 23.

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2012.07.012DOI Listing
December 2012

Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease.

Transplantation 2012 Dec;94(12):1250-7

Allogeneic Blood and Marrow Transplantation Program, Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0b013e3182708e7cDOI Listing
December 2012

Tale of two lymphomas: peripheral T-cell lymphoma after allogeneic stem-cell transplantation for marginal zone lymphoma.

J Clin Oncol 2012 Nov 10;30(31):e309-11. Epub 2012 Sep 10.

Niagara Health System, St Catharines, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.42.3582DOI Listing
November 2012

Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Biol Blood Marrow Transplant 2012 Oct 21;18(10):1589-99. Epub 2012 Apr 21.

Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2012.04.011DOI Listing
October 2012

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol.

Br J Haematol 2012 Aug 1;158(4):506-14. Epub 2012 Jun 1.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2012.09182.xDOI Listing
August 2012

A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia.

Blood 2011 Jun 3;117(25):6906-11. Epub 2011 May 3.

Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-01-329797DOI Listing
June 2011

Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?

Am J Hematol 2010 Nov;85(11):856-62

Chronic Myelogenous Leukemia Group, Department of Hematology/Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.21850DOI Listing
November 2010

The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.

Clin Cancer Res 2010 Nov 19;16(21):5339-50. Epub 2010 Oct 19.

Chronic Myelogenous Leukemia Group, Department of Hematology/Medical Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-10-1638DOI Listing
November 2010

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

Clin Cancer Res 2009 Jul 7;15(14):4750-8. Epub 2009 Jul 7.

Chronic Myelogenous Leukemia Group, Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0145DOI Listing
July 2009

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.

Br J Haematol 2009 Jun 4;146(1):76-85. Epub 2009 May 4.

Department of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.07712.xDOI Listing
June 2009